


## What is CanAssist Breast?

CanAssist Breast (CAB) is a prognostic test developed by OncoStem for eligible\* breast cancer patients. CAB is performed on patient's tumor sample removed during surgery and provides information about risk of breast cancer recurrence beyond what current conventional methods can offer. CAB determines whether a patient has "low- or high-risk" of breast cancer recurrence, which helps oncologists in deciding use of chemotherapy and/or additional therapies.



## How CAB works?



## What makes CAB unique?



First test to be developed and validated on Asian and Caucasian patients



Large Indian and international validation cohort



Machine Learning-based algorithm



Renowned validation partners in India, USA and Europe



Patented combination of biomarkers



CAP accredited ISO 13485 accredited ISO 15189 accredited



Publisted & presented in major international journals & conferences

\*Eligibility Criteria for CanAssist Breast: Stage I & II breast cancer patients with invasive breast carcinoma who have hormone-positive and HER2-negative tumours with 0-3 positive lymph nodes.

Turn around time: 8 working days

## **Download CanAssist Breast publications:**



Therapeutic Advances in Medical Oncology (2025) Vol 17



Cureus (2024) Vol 16



Cancer Medicine (2023) Vol 12



Breast Cancer Research (2023) Vol 25



Breast Cancer Research Treatment (2022) Vol 196



OncoStem Diagnostics Pvt. Ltd. #4, Raja Ram Mohan Roy Road, Aanand Tower, 2nd Floor, Bangalore - 560027 M: +91 96866 96505

E: info@oncostemdiagnostics.com

W: www.oncostem.com

